Spexis Provides Updates on Financial Audit, Moratorium, and Executive Changes

Spexis AG, a biopharmaceutical company, announced that its 2023 financial audit will not be completed by July 31, 2024. Consequently, it expects a temporary suspension of its stock trading by the SIX Exchange Regulation AG. This follows ongoing discussions about asset treatment under a provisional debt moratorium and disputes with major creditor SPRIM Global Investments and the termination of the ColiFin® license agreement.

Spexis is currently under an extended provisional moratorium until August 8, 2024. A court hearing on July 23, 2024, will consider the company’s request for a definitive moratorium. The company is engaged in fundraising and corporate partnering efforts. Absent new financing, Spexis faces the risk of liquidation or bankruptcy.

Effective August 1, 2024, Martin Jakobovic, Head of Finance and Acting CFO, will leave the company. Samuel Scheibler will become Head of Finance, while Muriel Fleming will take on the role of Chief Administrative Officer and Acting CFO.